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A B S T R A C T
The mitochondrial genome is present at variable copy number between individuals. Mitochondria are vulnerable
to oxidative stress, and their dysfunction may be associated with cardiovascular disease.
The association of mitochondrial DNA copy number with cardiometabolic risk factors (lipids, glycaemic
traits, inﬂammatory markers, anthropometry and blood pressure) was assessed in two independent cohorts of
European origin women, one in whom outcomes were measured at mean (SD) age 30 (4.3) years (N= 2278) and
the second at 69.4 (5.5) years (N= 2872). Mitochondrial DNA copy number was assayed by quantitative
polymerase chain reaction. Associations were adjusted for smoking, sociodemographic status, laboratory factors
and white cell traits.
Out of a total of 12 outcomes assessed in both cohorts, mitochondrial DNA copy number showed little or no
association with the majority (point estimates were close to zero and nearly all p-values were> 0.01). The
strongest evidence was for an inverse association in the older cohort with insulin (standardised beta [95%CI]:
−0.06, [−0.098, −0.022], p= 0.002), but this association did not replicate in the younger cohort.
Our ﬁndings do not provide support for variation in mitochondrial DNA copy number having an important
impact on cardio-metabolic risk factors in European origin women.
Author summary
Mitochondria are organelles that liberate adenosine triphosphate in
order to provide energy for a cell's requirements. Mitochondria contain
their own circular genome, which is present at variable copy number
between individuals. A number of predominantly small studies have
examined the relationship between mitochondrial DNA copy number
(mtDNA CN) and cardiometabolic traits. In one of the largest studies of
its kind, we have studied mtDNA CN in relation to a variety of cardi-
ometabolic risk factors in two large cohorts of European women. We
were able to make use of these rich data resources in order to control for
a range of confounding variables, including cellular heterogeneity. We
found no consistent evidence to suggest that mtDNA CN was related to
the cardiometabolic traits studied, although after considering multiple
testing, we did ﬁnd weak evidence of a positive association with cho-
lesterol in the younger cohort, and an inverse association with insulin in
the older cohort. This latter association has been reported more
consistently in previous literature. Whilst we cannot rule out associa-
tions between mtDNA CN and some cardiometabolic traits, our results
do not suggest that variation in mtDNA CN has a major impact on
cardio-metabolic risk factors in European origin women.
1. Introduction
Mitochondria are organelles responsible for the liberation of energy
in the form of adenosine triphosphate (ATP), which is hydrolysed to
meet a cell's energy requirements. Mitochondria contain a double-
stranded genome of 16.6 kb that encodes 37 genes, including the
complexes of the electron transport chain (Dimauro and Davidzon,
2005). The electron transport chain represents the end-point of cellular
respiration that facilitates ATP synthesis (Jonckheere et al., 2012).
Each mitochondrion contains a relatively constant (Jonckheere
et al., 2012; Ziegler et al., 2015) number of mitochondrial DNA
(mtDNA) (Wiesner et al., 1992), yet mitochondria number varies
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enormously according to cell lineage and function (Robin and Wong,
1988). This translates into considerable interindividual diﬀerences in
mtDNA content, and overall mtDNA copy number (mtDNA CN) has
been observed to decline with age (Short et al., 2005).
Hereditary mutations in nuclear DNA (nDNA) in genes controlling
mitochondrial deoxyribonucleoside triphosphate (dNTP) synthesis or
replication (reviewed elsewhere (El-Hattab and Scaglia, 2013)) may
lead to the autosomal recessive mitochondrial depletion syndromes
(MDS). Diseases resulting from mitochondrial depletion may be multi-
system, with organs relying heavily on aerobic metabolism (e.g. ske-
letal/cardiac muscle, liver, brain, kidney) (El-Hattab and Scaglia, 2013)
aﬀected most (Chinnery, 2014). Age of onset varies, although symp-
toms and signs are often most severe in childhood disease (Mattman
et al., n.d.).
Mitochondrial pathologies manifest clinically as the consequences
of respiratory chain dysfunction (Chinnery, 2014). Mitochondria are
the principal producers of reactive oxygen species (ROS), which may
damage lipids, proteins and nucleic acids, and mtDNA is exquisitely
vulnerable to ROS-induced damage (St John et al., 2007), which may
lead to ineﬃciency of the electron transport chain, and further ROS
production (Ziegler et al., 2015).
MtDNA CN has been associated with cardiovascular disease
(Moslehi et al., 2012; Chen et al., 2014; Huang et al., 2016) and its risk
factors, chronological age (Mengel-From et al., 2014), as well as mar-
kers and diseases associated with age, e.g. telomere length (Kim et al.,
2012a; Kim et al., 2013; Qiu et al., 2015; Sahin et al., 2011), and frailty
(Ashar et al., 2015). Cognitive phenotypes associated with decreased
mtDNA CN include cognitive impairment (Lee et al., 2010), dementia
(Coskun et al., 2004; Coskun et al., 2012; Gatt et al., 2013; Podlesniy
et al., 2013; Rice et al., 2014), and psychiatric morbidities (depression
(Kim et al., 2011; Chang et al., 2015) bipolar disorder (Chang et al.,
2014; De Sousa et al., 2014), and post-traumatic stress disorder [PTSD])
(Bersani et al., 2016). For detail, see Online Resource 1, Online Re-
source 2, and Online Resource 3.
Studies have generally found an inverse correlation between mtDNA
CN and cardio-metabolic risk factors and outcomes (Kim et al., 2012b;
Huang et al., 2011; Antonetti et al., 1995; Chien et al., 2012; Kaaman
et al., 2007; Lindinger et al., 2010; Ding et al., 2015), although a
number of studies have also found null (Ding et al., 2015; Asmann et al.,
2006; Mozhei et al., 2014), tissue-dependent (Hsieh et al., 2011), or
results in the opposite direction (Lee et al., 2014; Malik et al., 2009;
Weng et al., 2009). Elevated low-density lipoprotein cholesterol (LDLc)
has also been associated with decreased mtDNA CN, with the inverse
association reported for high-density lipoprotein cholesterol (HDLc)
(Lee et al., 2014; Liu et al., 2005), and a recent case-control study found
that mtDNA CN was generally lower in coronary heart disease (Chen
et al., 2014). However, whilst mtDNA is heritable (Ding et al., 2015),
and the majority of studies have conceptualised mtDNA CN as an ex-
posure, reverse causation is possible: recently, an axis proposed be-
tween mitochondria, telomeres and p53 has been discussed (Sahin and
DePinho, 2012), suggested that telomere dysfunction and attrition may
be associated with impaired mitochondrial function (Kim et al., 2013).
The majority of studies relating mtDNA CN to cardiometabolic traits
have been of small sample size (in the order of tens to hundreds of
patients, with one recent larger study analysing 2077 patients) (Ding
et al., 2015). We studied observational associations between mtDNA CN
and cardiometabolic risk factors in two large, independent cohorts of
European origin: mothers of the Avon Longitudinal Study of Parents
and Children (ALSPAC) study, and participants of the British Women's
Heart and Health Study (BWHHS) cohort, a population-based cohort of
post-menopausal women. Longitudinal associations were studied in
ALSPAC, and cross-sectional associations were studied in BWHHS. We
used these rich data sources to control for potential confounding vari-
ables. Since the relationship between mtDNA CN and leucocyte sub-
types is well-documented, and may bias mtDNA CN analyses (Urata
et al., 2008; Knez et al., 2016), we also examined the association
between mtDNA CN and white cell traits (Pyle et al., 2010).
2. Methods
2.1. Cohort details
2.1.1. ALSPAC
The Avon Longitudinal Study of Parents and Children is a pro-
spective cohort of mothers and children. Between 1991 and 1992,
14,541 women living in the former county of Avon, UK were recruited
during pregnancy, of whom 13,761 were enrolled into the study.
Antenatal blood samples were assayed for mtDNA CN in this study.
Participants have been followed up longitudinally since recruitment.
Outcome data are those measured at the Focus on Mothers Research
Clinic, which took place between 2008 and 2011. Further details are
available in the cohort proﬁle paper (Fraser et al., 2013), and the study
website contains details of available data through a fully searchable
data dictionary: http://www.bris.ac.uk/alspac/researchers/data-
access/data-dictionary/.
Ethical approval for the study was obtained from the ALSPAC Ethics
and Law Committee and the Local National Health Service (NHS)
Research Ethics Committees.
2.1.2. BWHHS
The British Women's Heart and Health Study (BWHHS) recruited
4286 women between the ages of 60–79 from UK general practices
[https://www.lshtm.ac.uk/eph/ncde/research/bwhhs/]. Blood was
collected at baseline interview (1999–2001) after an overnight or
minimum 6-h fast. Details of the sampling strategy and available data,
including details of follow-up and data linkage, are described elsewhere
(Lawlor et al., 2003). Data for the current analysis are those taken or
derived at baseline, unless otherwise stated. Ethical approval for the
BWHHS was obtained from NHS Research Ethics Committees of in-
dividual centres, in addition to the London Medical Research Ethics
Committee.
2.2. Assay of mitochondrial DNA copy number
ALSPAC mothers' DNA was extracted from whole blood or white cell
pellet samples (anticoagulated with EDTA and heparin, respectively)
using a phenol-chloroform method. For BWHHS a salting-out procedure
was used to extract DNA from K-EDTA whole blood samples (Zabaneh
et al., 2011).
MtDNA CN was measured using a quantitative PCR (qPCR) assay
that relates the relative copy number of a mitochondrial DNA amplicon
[bases 317–381 in the D-loop region] to a nuclear reference gene [B2M]
(Malik et al., 2011). For details of the assay, see Online Resource 4.
MtDNA CN was calculated as the relative magnitude of the signal
from the mitochondrial amplicon to the nuclear amplicon. PCR eﬃ-
ciency values were calculated from standard curves to adjust raw va-
lues, and ‘calibrator’ DNAs were ampliﬁed on each microplate, in order
to generate a ‘calibration factor’ for each batch. This factor was applied
to the previously calculated copy numbers, resulting in eﬃciency- and
calibrator- adjusted value for mtDNA CNs.
2.3. Outcome variables
Unless otherwise stated, outcomes were measured at baseline in
BWHHS, and at the Focus on Mothers Research Clinic (2008–2011) in
ALSPAC.
2.3.1. Anthropometric variables
After measuring height and weight, BMI was calculated as weight
(kg)/height (m2). Averages of two measures of waist and hip cir-
cumference were calculated, and waist-to-hip ratio was derived.
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2.3.2. Blood pressure
Systolic and diastolic blood pressure (BP) was measured in both
ALSPAC and BWHHS.
2.3.3. Biomarkers
Fasting lipids (total cholesterol, HDLc, LDLc, triglycerides, fasting
glucose (all mmol/L), insulin (u/mL) and C-reactive protein (CRP) (mg/
L) were measured in ALSPAC and BWHHS. Data on interleukin-6 (IL6)
(pg/mL) were also available for BWHHS. Descriptive summaries are
given in Table 1.
2.4. Confounding variables
2.4.1. Sociodemographic variables
Age, as well as smoking and socioeconomic factors are associated
with cardiovascular disease (Lawlor et al., 2005). mtDNA has been
observed to decline with age (Mengel-From et al., 2014) and may also
be associated with smoking and socioeconomic position (Hosnijeh
et al., 2014), and for these reason, these variables were chosen as
possible confounders.
For ALSPAC, age was recorded as age at delivery, which approxi-
mated age at DNA sampling. Age at baseline was available for BWHHS.
Analyses were restricted to women of self-reported ‘white’ ethnicity.
In ALSPAC, smoking was quantiﬁed as the number of cigarettes
smoked per day shortly pre-pregnancy, (0, 1–4, 5–9, 10–14, 15–19,
20–24, 25–29,> 30). Smoking was quantiﬁed at baseline in BWHHS (0
[never smoker], 0 [ex-smoker], 1–9, 10–19, 20–29,> 30). For de-
scriptive analyses, smoking is recoded into smokers/‘non-smokers.
In ALSPAC, highest education level was divided into: Vocational,
CSE (Certiﬁcate of Secondary Education, ‘O’ (Ordinary) Level, ‘A’
(Advanced) level, or degree. Four categories of the Standard
Occupational Classiﬁcation classiﬁed occupational class: I, II, III [non-
manual], plus a collapsed category (III [manual], IV, V, and Armed
Forces) (Oﬃce for National Statistics, E. L, et al., 2000). For BWHHS,
continuous measures of employment and education score by neigh-
bourhood were used (according to the Indices of Deprivation [2000]),
where a higher score indicates greater deprivation, except in descriptive
tables, wherein occupation was classiﬁed as for ALSPAC (with those
missing occupational status data coded to ‘manual’) (Indices of
Deprivation 2000, 2000).
2.4.2. DNA concentration and source
DNA sample concentration (ng/μl) was measured by a PicoGreen®
ﬂuorescence-based method. We have observed a negative correlation
between the obtained mtDNA CN and initial stock DNA concentration,
from which working concentrations were prepared (Malik et al., 2011),
and so controlled for this in our analyses. Since we observed a lower
mtDNA CN in whole blood samples, which may be due to diﬀering cell
proportions, we also adjusted for this covariate, as DNA was from either
whole blood or white cell pellets in ALSPAC.
2.4.3. Cell counts
Diﬀerent white cell lineages may contain diﬀerent numbers of mi-
tochondria, and hence mtDNA: (Pyle et al., 2010) e.g., neutrophils
contain a relative paucity of mitochondria compared to lymphocytes.
Platelets, which are anucleate, and yet mitochondria-rich, may also
alter the interpretation of assayed mtDNA CNs (Urata et al., 2008). In
order to assess the relationship between mtDNA CN and
Table 1
Characteristics of BWHHS and ALSPAC cohorts.
Variable ALSPAC BWHHS
Units Mean/Mediana SD/IQRa N Units Mean/Mediana SD/IQRa N Pe
mtDNA ratio 45.5d 37.9–56.4d 2278 ratio 25.8 20.4–31.7 2872 < 1e-06
DNA concn. b ng/uL 158 76–304 2278 ng/uL 300 210–407 2872 < 1e-06
DNA source % whole blood samples 39.6 2278
Age (baseline) years 30 4.3 2278 years 69.4 5.5 2872 < 1e-06
Education %≤GCSE 51.4 2278 score −0.0643 0.89 2872
Occupation % manual 14 2278 % manual 54.9 2872 < 1e-06
Smoking % current 20.5 2278 % current 9.64 2872 < 1e-06
Total cholesterolb mmol/L 4.83 4.32–5.4 2050 mmol/L 6.6 5.9–7.4 2854 < 1e-06
HDL cholesterolb mmol/L 1.44 1.2–1.7 2050 mmol/L 1.6 1.4–2 2850 < 1e-06
LDL cholesterolb mmol/L 2.9 2.41–3.43 2050 mmol/L 4.1 3.4–4.8 2793 < 1e-06
Triglyceridesb mmol/L 0.88 0.68-1.17 2050 mmol/L 1.6 1.2–2.22 2854 < 1e-06
Fasting glucoseb mmol/L 5.15 4.91–5.44 2050 mmol/L 5.8 5.4–6.2 2847 < 1e-06
Insulinb u/mL 4.57 3.23-6.75 2044 u/mL 6.4 4.4–9.9 2859 < 1e-06
Interleukin-6b pg/mL 2.12 1.47–3.11 2796
C-reactive proteinb mg/L 0.98 0.48–2.1 2050 mg/L 1.92 0.948–4.13 2680 < 1e-06
Body Mass Index kg/m^2 25.4 22.8–29 2266 kg/m2 26.7 24–30.1 2841 < 1e-06
Waist-Hip Ratio ratio 0.809 0.065 2267 ratio 0.819 0.068 2827 < 1e-06
Height cm 164 6.1 2269 cm 159 6.1 2842 < 1e-06
Systolic BP mmHg 118 12 2214 mmHg 147 25 2860 < 1e-06
Diastolic BP mmHg 71.4 7.9 2214 mmHg 79.4 12 2860 < 1e-06
Lymphocytesb Lymphocyte proportion 0.261 0.091 491 All ×103/ml 1.97 1.57–2.43 2872
Granulocytesc All proportion 0.683 0.083 491 Neut. ×103/mL 4.14 3.36–5.14 2872
Baso. ×103/mL 0.06 0.04–0.08 2872
Eos. ×103/mL 0.13 0.08–0.19 2872
Monocytesc All proportion 0.0782 0.022 491 ×103/mL 0.3 0.2–0.4 2872
Platelets ×103/mL 281 71 2872
Other abbreviations: mtDNA = Z-scored, log-transformed mtDNA copy number; conc. = concentration; HDL, LDL = High-, low-density lipoprotein; BP = blood pressure;
GCSE = General Certiﬁcate of Secondary Education (or ‘O’-level); Neut. = Neutrophils; Baso. = Basophils; Eos. = Eosinophils.
a Means (standard deviations [SD]) are shown for continuous variables, medians (interquartile range [IQR]), if skewed.
b Variable skewed.
c Skewed in BWHHS only.
d Calculated using eﬃciency-adjusted crossing points (Cps) for the nuclear and mitochondrial amplicons, using the equation: mtDNA CN = (2^(nuclear DNA Cp – mitochondrial DNA
Cp)).
e P values are for either Mann-Whitney U (Skewed continuous variables), independent t-tests (for continuous normal variables, assuming unequal variance for age), or chi-square test
(categorical variables).
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cardiometabolic risk factors independent of cellular heterogeneity,
latter models adjusted for cell populations. Cell counts were not directly
assayed in ALSPAC. However, the ‘ARIES’ subset (Relton et al., 2015) of
the cohort have been assayed using the Illumina Inﬁnium Hu-
manMethylation450 BeadChip (Illumina 450 K) array. DNA methyla-
tion proﬁles may be used in order to infer proportions of various cel-
lular populations in samples assayed on high dimension methylation
arrays, such as the Illumina 450 K array. The most popular algorithm to
achieve this goal is the ‘Houseman’ method (Houseman et al., 2012),
which uses individual ‘methylation signatures’ of samples as a proxy for
the distribution of white cells in combination with a training set of
samples of puriﬁed white cells. This method has been applied pre-
viously to individuals belonging to the ARIES subset of ALSPAC
(Richmond et al., 2015), implemented using the ‘estimateCellCounts’
function of the R package ‘minﬁ’ (Jaﬀe and Irizarry, 2014). Proportions
of CD4+ and CD8+ T lymphocytes (CD4T, CD8T), B lymphocytes,
Natural Killer (NK) cells, Monocytes, and Granulocytes were estimated.
One variable for lymphocyte proportion was derived by adding CD8T,
CD4T, and B- lymphocyte proportions (NK cells were not included so as
to avoid perfect prediction) and we used this to adjust for cell type.
In BWHHS, absolute count of platelets, basophils, eosinophils,
neutrophils, lymphocytes and monocytes were assayed at baseline.
2.5. Missing data
MtDNA CN data from 8158 ALSPAC and 3673 BWHHS women were
available. 2278 ALSPAC and 2872 BWHHS participants also had data
on age at DNA sampling, DNA concentration, occupational class, edu-
cation level, smoking, plus≥ 1 outcome variable. In addition, all 2872
BWHHS women had cell count data. Cell proportion data were only
available for a subset of the 2278 ALSPAC women [max N= 491].
Four ALSPAC and four BWHHS participants were removed from the
analysis as they had severely outlying values, either considered im-
plausible and/or as biasing regression estimates by excessive leverage.
2.6. Statistical analysis
Table 1 shows descriptive data. Means (standard deviations, SD) are
presented for normally distributed data. In the case of non-normality,
medians (interquartile ranges, IQR) are shown. Means are compared
with independent sample t-tests (assuming unequal variance for ‘age’,
given the uniform sampling in BWHHS); medians are compared with
the Mann-Whitney U test. Categorical variables were compared using a
chi-squared test (1 degree of freedom). Haematological variables were
not comparable, as ALSPAC data were estimated cell proportions,
whereas BWHHS data were cell counts.
To assess relationships between mtDNA CN and covariates in each
cohort, independent sample t-tests were performed for binary covari-
ates, and Pearson's correlation coeﬃcients were computed for con-
tinuous (log-transformed variables were used in cases of positive skew)
(see Tables 2–3).
For the main analyses, positively skewed outcomes were log-trans-
formed where this led to a better approximation of normality.
Outcomes were then z-scored to yield standardised regression coeﬃ-
cients. Waist-hip ratio, height, and BP were not transformed as their
distributions were approximately normal.
Regression analyses of Z-scored outcomes on Z log mtDNA are
presented for ALSPAC and BWHHS. M1 was unadjusted, and M2 was
adjusted for age at DNA sampling (continuous), education (categorical
for ALSPAC, continuous for BWHHS), smoking status (assuming line-
arity over categories), occupational class (categorical), DNA con-
centration (continuous) and DNA source (categorical, ALSPAC only).
M3 additionally adjusted for cell counts (as estimated proportions
[ALSPAC], and counts [BWHHS] — see Table 3).
With the exception of mtDNA CN (which was logged to facilitate Z-
scoring, with z-scores for mtDNA CN being calculated before merging Ta
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with phenotype data), none of the other independent variables in
Tables 2–3 were log-transformed for the purpose of regression models.
Residual-versus-ﬁtted values plots and quantile-quantile plots were
examined, in order to check assumptions of normally distributed re-
siduals, homoscedasticity, and linearity.
Sensitivity analyses were carried out for ALSPAC, which ﬁtted
models M1-M3 separately for those ALSPAC Mothers with DNA ex-
tracted from white cells and whole blood.
Both ﬁxed- and random-eﬀects meta-analyses of the ALSPAC and
BWHHS results were performed using the R package ‘meta’.
Analyses were undertaken using R 3.2.4.
2.7. Multiple testing
Nyholt's method of spectral decomposition was used to calculate the
eﬀective number of independent tests from correlation matrices of
outcomes (calculated separately for ALSPAC and BWHHS) (Nyholt,
2004). The p values presented are not corrected for multiple testing, but
the number of independent tests are reported for reference.
3. Results
3.1. Descriptives
Descriptive statistics for ALSPAC and BWHHS are shown in Table 1.
The mean (SD) age of participants was 69.4 (5.5) years in BWHHS, and
30.0 (4.3) years in ALSPAC. ALSPAC women were more likely to smoke
(yet 32.7% of BWHHS women were ex-smokers). Fewer in ALSPAC had
a manual occupation, and ALSPAC mothers were educated to a higher
level. ALSPAC participants had healthier levels of cardiovascular risk
factors (including lower total cholesterol, LDLc, fasting glucose and
insulin); they were also taller and leaner, with lower blood pressure.
Median (IQR) mtDNA CN was higher in ALSPAC women: 45.5
(37.9–56.4) compared to 25.8 (20.4–31.7) in BWHHS (Mann Whitney U
p < 1e-06). However, DNA extraction method diﬀered between the
two cohorts (phenol for ALSPAC, salting-out for BWHHS) and so these
diﬀerences may partially be attributable to laboratory factors.
3.2. Confounding variables and laboratory covariates
Relationships between potential confounding variables, laboratory
covariates and mtDNA CN (all subsequent analyses use Z-scores of
logged mtDNA) are shown in Table 2. DNA concentration was inversely
associated with mtDNA in both cohorts (mean diﬀerence: −0.170
[−0.209, −0.130], p= 3.28e-16 [ALSPAC]; −0.229 [−0.263,
−0.194], p≤2e-16 [BWHHS]). In ALSPAC, mtDNA CN was lower in
those women from whom DNA was extracted from whole blood (mean
diﬀerence: −0.367 [−0.447, −0.287], p < 2e-16).
Whilst mtDNA CN was lower in BWHHS (see Table 1, p < 1e-06 for
independent t-test assuming unequal variance), there was no evidence
of an association between mtDNA count and age within ALSPAC or
BWHHS, nor with and smoking. There was a negative association be-
tween socioeconomic status and mtDNA CN in BWHHS (Pearson's R:
−0.097 [95%CI:−0.133,−0.061], p= 1.77e-07 for education score,
where a higher score indicates lower level of education); mean diﬀer-
ence: -0.102 [95%CI:-0.175, −0.029], p= 0.006 for manual occupa-
tion), but not in ALSPAC.
The correlations of mtDNA CN with haematological parameters
varied by cell type (see Table 3): positive associations were observed for
proportions (in ALSPAC) and counts (in BWHHS) of lymphocytes and
monocytes (although monocytes had considerably stronger evidence of
association in BWHHS), and for additional counts assayed only in
BWHHS (platelet, basophil and eosinophil count). Negative associations
were observed between mtDNA and granulocyte proportion in ALSPAC,
and neutrophil count in BWHHS (notably, neutrophils make up the
majority of circulating granulocytes). Although cell data were propor-
tions for ALSPAC and counts for BWHHS, eﬀect sizes were similar in
both cohorts (see Table 3).
3.3. Regression models
The spectral decomposition method of Nyholt (2004) estimated that
10 and 11 independent tests were carried out in ALSPAC and BWHHS,
respectively.
Out of a total of 12 outcomes assessed in both cohorts, mtDNA
showed little or no association with the majority (point estimates were
close to zero, or attenuated after adjustment).
3.3.1. ALSPAC
Before adjustment for cell counts, there was weak evidence of a
positive association with waist-hip ratio and mtDNA CN (standardised
beta: [95% CI]: 0.060 [0.017, 0.104], p= 0.007). After adjusting for
cell counts (M3) there was very weak evidence of a positive association
between mtDNA CN and total cholesterol (standardised beta: [95% CI]:
0.098 [−0.008, 0.204], p= 0.070) (see Table 4). However, this asso-
ciation was also consistent with the null eﬀect, and it did not replicate
in BWHHS.
Sensitivity analyses for ALSPAC repeated models M1–M3, but were
stratiﬁed by whether women had DNA extracted from white cells, or
whole blood (see Online Resource 5 for results). After stratiﬁcation, the
results were broadly consistent with the combined analyses in Table 4.
After restricting the analysis to whole blood samples, mtDNA CN was
weakly associated with total cholesterol, LDLc and triglycerides. Al-
though this association did not survive cell-proportion adjustment, this
is likely to be a function of power. Whilst these eﬀect sizes were di-
rectionally concordant in the (larger) white cell analysis, they were also
consistent with the null.
Table 3
Pearson's correlation coeﬃcients between haematological parameters and log z-scored mtDNA CN in ALSPAC and BWHHS.
Cell type ALSPACa BWHHS
Subtype Units r 95%LCI 95%UCI P N Subtype Units r 95%LCI 95%UCI P N
Lymphocytesb All Proportion 0.279 0.195 0.359 3.18e-10 491 All ×103/ml 0.159 0.123 0.195 9.90e-18 2872
Granulocytesc All Proportion −0.362 −0.436 −0.282 1.22e-16 491 Neutrophils** ×103/mL −0.072 −0.108 −0.035 1.14e-04 2872
Basophils** ×103/mL 0.055 0.018 0.091 3.24e-03 2872
Eosinophils** ×103/mL 0.047 0.010 0.083 1.25e-02 2872
Monocytesc Proportion 0.125 0.037 0.212 5.39e-03 491 ×103/mL 0.087 0.051 0.123 2.98e-06 2872
Plateletsc ×103/mL 0.062 0.026 0.098 8.77e-04 2872
Abbreviations: r = Correlation coeﬃcient, 95% LCI/UCI = Lower and upper 95% conﬁdence interval bounds.
a Cell count data are estimated from Illumina 450 k Methylation data for ALSPAC, and for BWHHS, data are from actual full blood count assays. In ALSPAC, DNA is extracted from
either white cells or whole blood, whereas all BWHHS DNA is extracted from whole blood.
b log-transformed.
c log-transformed in BWHHS only.
A.L. Guyatt et al. Mitochondrion 39 (2018) 9–19
13
3.3.2. BWHHS
In BWHHS, the most consistent relationship that survived adjust-
ment in the ﬁnal model, M3, was a negative association between
mtDNA and insulin (standardised beta [95%CI]: −0.060 [−0.098,
−0.022], p= 0.002) (see Table 5), but again, there was no evidence of
this association in ALSPAC.
3.3.3. Meta-analysis
Results of random-eﬀects analyses for ALSPAC Mothers and BWHHS
are shown in Figs. 1 and 2 (and additionally tabulated in Online Re-
source 6). Fig. 2 only combines those with mtDNA CN assayed from
whole blood (all of BWHHS and a subset of ALSPAC Mothers). After
meta-analysing all participants in model 3, there was weak evidence of
a negative association between systolic and diastolic blood pressure and
Z log mtDNA in ﬁxed-eﬀects analyses (I2 = 0%) (see Fig. 1). On re-
stricting the analysis to just those ALSPAC Mothers with mtDNA CN
assayed from whole blood, heterogeneity was generally reduced, but
associations were broadly similar. In this analysis (see Fig. 2), there was
still some evidence for an association of mtDNA CN with diastolic blood
pressure, and additionally, more evidence for a negative association
with insulin (beta: [95% CI]: −0.057 [−0.094, 0.020], p= 0.003,
I2 = 0). However, it should be noted that an even smaller number of
ALSPAC women contributed to this analysis, so the associations were
primarily driven by BWHHS.
4. Discussion
This is one of the largest studies to examine the association of mi-
tochondrial copy number (as measured by a quantitative qPCR assay)
with a range of cardiometabolic traits in general population samples. In
addition, it is amongst a relatively small number of studies to have
controlled for haematological parameters (Knez et al., 2016; Tin et al.,
2016).
We observed little evidence for associations of cardiometabolic
traits with mtDNA CN. A negative association between mtDNA CN and
insulin was unique to BWHHS. The trend observed for the association
with lipids in ALSPAC (a positive relationship between mtDNA and
total cholesterol) is at odds with the direction of association reported in
the literature (Huang et al., 2011). There was also a trend towards an
inverse association between mtDNA CN and BMI (observed in ALSPAC
only). The association between high insulin and low mtDNA is con-
cordant with previous observations that diabetes and insulin resistance
are generally associated with lower mtDNA CN (Chien et al., 2012;
Hsieh et al., 2011; Rolo and Palmeira, 2006). Although we did not
observe this same association in the ALSPAC mothers, the cohorts are of
diﬀerent ages; it is therefore possible that a lower prevalence of insulin
Table 4
Standardised linear regression of cardiovascular traits on mtDNA CN (ALSPAC).
Outcome M1 M2 M3
B LCI UCI P N B LCI UCI P N B LCI UCI P N
Cholesterola 0.061 0.016 0.106 0.008 2050 0.058 0.012 0.103 0.013 2050 0.098 −0.008 0.204 0.070 465
HDLa 0.022 −0.024 0.067 0.348 2050 0.015 −0.031 0.061 0.535 2050 −0.005 −0.109 0.099 0.929 465
LDLa 0.036 −0.009 0.081 0.118 2050 0.037 −0.009 0.083 0.117 2050 0.069 −0.038 0.177 0.206 465
Triglyceridesa 0.055 0.010 0.101 0.016 2050 0.046 −0.001 0.092 0.054 2050 0.083 −0.025 0.192 0.133 465
Glucosea 0.019 −0.026 0.065 0.401 2050 0.022 −0.025 0.069 0.350 2050 0.049 −0.056 0.154 0.362 465
Insulina 0.012 −0.033 0.057 0.603 2044 0.022 −0.025 0.069 0.360 2044 0.014 −0.094 0.122 0.796 464
C-reactive proteina 0.015 −0.030 0.060 0.513 2050 0.012 −0.035 0.058 0.615 2050 −0.054 −0.165 0.056 0.336 465
Body Mass Indexa −0.010 −0.052 0.033 0.656 2266 −0.004 −0.048 0.040 0.862 2266 −0.098 −0.205 0.009 0.074 488
Waist-Hip Ratio 0.052 0.009 0.094 0.018 2267 0.060 0.017 0.104 0.007 2267 −0.005 −0.108 0.099 0.929 489
Height −0.021 −0.064 0.021 0.330 2269 −0.021 −0.065 0.023 0.350 2269 −0.046 −0.151 0.060 0.397 489
Systolic BP 0.025 −0.018 0.068 0.260 2214 0.027 −0.018 0.071 0.241 2214 −0.048 −0.153 0.056 0.363 473
Diastolic BP 0.010 −0.033 0.053 0.650 2214 0.015 −0.030 0.060 0.512 2214 −0.069 −0.173 0.035 0.196 473
Abbreviations: M1 =Model 1 (unadjusted); M2 =Model 2 (adjusted for age at DNA sampling, DNA source, education level, smoking status, occupational class, DNA concentration);
M3 = Model 3 (as M2, plus adjustment for cell counts as described in Table 3). B = Standardised beta coeﬃcient; LCI = 95% conﬁdence interval (lower bound); UCI = 95% conﬁdence
interval (upper bound); HDL, LDL = High-, Low-density lipoprotein cholesterol. BP = blood pressure.
a log-transformed.
Table 5
Standardised linear regression of cardiovascular traits on mtDNA CN (BWHHS).
Outcome M1 M2 M3
B LCI UCI P N B LCI UCI P N B LCI UCI P N
Cholesterola 0.031 −0.006 0.067 0.102 2854 0.031 −0.006 0.069 0.102 2854 0.013 −0.025 0.051 0.510 2854
HDLa −0.055 −0.092 −0.018 0.003 2850 −0.058 −0.095 −0.021 0.002 2850 −0.020 −0.058 0.017 0.284 2850
LDLa 0.055 0.018 0.092 0.004 2793 0.041 0.003 0.079 0.033 2793 0.024 −0.014 0.063 0.214 2793
Triglyceridesa −0.005 −0.042 0.031 0.774 2854 0.028 −0.009 0.065 0.136 2854 −0.019 −0.056 0.018 0.316 2854
Glucosea −0.028 −0.065 0.009 0.132 2847 −0.019 −0.056 0.019 0.330 2847 −0.023 −0.062 0.015 0.234 2847
Insulina −0.058 −0.095 −0.021 0.002 2859 −0.034 −0.072 0.003 0.073 2859 −0.060 −0.098 −0.022 0.002 2859
Interleukin-6a −0.022 −0.059 0.015 0.240 2796 0.013 −0.024 0.050 0.484 2796 −0.001 −0.037 0.034 0.938 2796
C-reactive proteina −0.024 −0.062 0.014 0.212 2680 0.003 −0.036 0.042 0.876 2680 −0.006 −0.043 0.032 0.771 2680
Body Mass Indexa 0.027 −0.010 0.064 0.147 2841 0.046 0.008 0.083 0.017 2841 0.016 −0.022 0.054 0.421 2841
Waist-Hip Ratio −0.016 −0.053 0.021 0.386 2827 0.004 −0.034 0.041 0.854 2827 −0.021 −0.060 0.017 0.271 2827
Height −0.011 −0.048 0.025 0.546 2842 −0.032 −0.069 0.004 0.085 2842 −0.028 −0.065 0.009 0.144 2842
Systolic BP −0.036 −0.073 0.000 0.051 2860 −0.019 −0.055 0.017 0.297 2860 −0.033 −0.070 0.004 0.079 2860
Diastolic BP −0.042 −0.078 −0.005 0.026 2860 −0.033 −0.070 0.004 0.082 2860 −0.041 −0.079 −0.003 0.036 2860
Abbreviations: M1 = Model 1 (unadjusted); M2 = Model 2 (adjusted for age at DNA sampling, education level, smoking status, occupational class, DNA concentration); M3 = Model 3
(as M2, plus adjustment for cell counts as described in Table 3). B = Standardised beta coeﬃcient; LCI = 95% conﬁdence interval (lower bound); UCI = 95% conﬁdence interval (upper
bound); HDL, LDL = High-, Low-density lipoprotein cholesterol; BP = blood pressure.
a log-transformed.
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resistance amongst the younger population is the reason that we did not
observe the association in these individuals. We additionally saw weak
evidence of an association between higher mtDNA CN and lower blood
pressure after meta-analysis, but this did not survive multiple testing
correction. Overall, the small number of associations that we see do not
replicate within our cohorts or with published literature and suggest
that beyond chance there is little evidence that mtDNA CN is an im-
portant determinant or predictor of cardio-metabolic risk in European
origin women. Despite this, some studies have observed that mtDNA is
related to sex (Ashar et al., 2015; Purdue et al., 2012), and ethnicity
(Purdue et al., 2012). Whilst our cohorts are comparable to one another
in terms of these characteristics, it is possible that our results may not
necessarily be generalisable to other populations, for example, if there
are interactions between mtDNA CN and cardiometabolic risk factors
according to these characteristics.
The literature studying mtDNA and components of the metabolic
syndrome has been reported in such a way that suggests inconsistency:
in those papers studying metabolic syndrome, hyperlipidaemia (of
LDLc) or adiposity, most reported an inverse association (Kim et al.,
2012b; Huang et al., 2011; Kaaman et al., 2007; Lindinger et al., 2010;
Fig. 1. Random-eﬀects meta-analysis of model M3. Forest plot showing random-eﬀects meta-analyses of fully-adjusted model (M3) of associations observed in ALSPAC and BWHHS. For
reference, the eﬀect sizes of the individual associations between mtDNA and outcome variables in ALSPAC and BWHHS are also shown on the forest plots, with meta-analysis summary
estimates shown as diamonds. Abbreviations: Chol = total cholesterol; HDL = High-density LDL cholesterol; LDL = Low-density lipoprotein cholesterol; TG = triglycerides;
Gluc = Fasting glucose; Ins = Insulin; CRP = C-reactive protein; BMI = Body Mass Index; WHR=Waist-Hip Ratio; Ht = height; SBP = systolic blood pressure; DBP = Diastolic blood
pressure; 95%LCI/UCI = lower and upper bounds of 95% conﬁdence interval. N = Sample size, I^2 = I2 statistic for heterogeneity.
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Mozhei et al., 2014; Lee et al., 2014), with some reporting the opposing
direction (Lindinger et al., 2010; Lee et al., 2014). Results are more
equivocal in the diabetes literature, with positive (Malik et al., 2009;
Weng et al., 2009), inverse (Antonetti et al., 1995; Chien et al., 2012;
Hsieh et al., 2011) and no associations (Lindinger et al., 2010) reported.
Notably, the literature contains cross-sectional, longitudinal, and tissue-
speciﬁc studies, and both clinical (such as patients with diabetes) and
general population samples (e.g. studying hyperglycaemia in a popu-
lation sample); it is plausible that the results from clinical samples are
not generalisable to the associations observed at the population level.
Finally, the sample sizes of the majority of papers are small, it is dif-
ﬁcult to discern whether the variation reported in the literature re-
presents true heterogeneity of eﬀect, or chance variation around a null
eﬀect.
Since mitochondrial load varies by leucocyte subtype, we assessed
the relationship between mtDNA count and blood cell data. Platelets
contain no nDNA, yet an abundance of mitochondria, and thus may
artiﬁcially inﬂate mtDNA CN, as reported previously (Urata et al.,
2008). Neutrophils reportedly contain up to 10–15 times fewer mi-
tochondria than peripheral blood mononuclear cells (PBMCs) (Maianski
Fig. 2. Random-eﬀects meta-analysis of model M3 (sensitivity). Forest plot showing random-eﬀects meta-analyses of fully-adjusted model (M3) of associations observed in ALSPAC
(whole blood samples only) and BWHHS. For reference, the eﬀect sizes of the individual associations between mtDNA and outcome variables in ALSPAC and BWHHS are also shown on
the forest plots, with meta-analysis summary estimates shown as diamonds. Abbreviations: Chol = total cholesterol; HDL = High-density LDL cholesterol; LDL = Low-density lipoprotein
cholesterol; TG = triglycerides; Gluc = Fasting glucose; Ins = Insulin; CRP = C-reactive protein; BMI = Body Mass Index; WHR=Waist-Hip Ratio; Ht = height; SBP = systolic blood
pressure; DBP = Diastolic blood pressure. 95%LCI/UCI = lower and upper bounds of 95% conﬁdence interval. N = Sample size, I^2 = I2 statistic for heterogeneity.
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et al., 2004), and accordingly, they exhibited a negative relationship
with mtDNA count. PBMCs are mitochondria rich, with ‘granulocyte
mtDNA CN observed as lower than lymphocyte and monocyte copy
number’ (Pyle et al., 2010). Importantly, despite having absolute counts
in BWHHS but only estimated proportions in ALSPAC, the direction and
magnitude of the associations between cell types and mtDNA CN were
comparable.
Whilst these results demonstrate how important it may be to control
for cell populations when performing mtDNA association analyses, cell
counts could also mediate an association between mtDNA and cardio-
vascular disease, via inﬂammation (white cells, in particular macro-
phages, have a causal role in atherosclerosis) (Yu et al., 2013). In this
case, controlling for these variables may be overly conservative.
There are several limitations to this work. Whilst the mtDNA assay
was undertaken by one individual using identical protocols in both
studies, DNA extraction was undertaken with diﬀerent methods; by a
phenol-chloroform method in ALSPAC and by ‘salting out’ in BWHHS.
We computed Z-scores so that the magnitude of eﬀect sizes between the
two cohorts were comparable, yet nonetheless, if extraction method has
an eﬀect on the precision or linearity of the mtDNA assay, this could
introduce bias, though the consistent null associations for the vast
majority of results between the two studies suggests major bias from
this source is unlikely. Furthermore, mtDNA CN was assayed from ei-
ther whole blood or white cell DNA samples in ALSPAC. Whilst we
controlled for sample type as a covariate in models M2 and M3, it is
possible that this could bias our results, since we were not able to
control for other cell populations in the ALSPAC whole blood sample,
such as platelets. Nevertheless, we did not observe major diﬀerences
between the directions of associations observed in a sensitivity analysis
that stratiﬁed the ALSPAC sample by whether mtDNA CN was assayed
from whole blood or white cells, although the heterogeneity (quantiﬁed
by the I2-statistic) (Higgins et al., 2003) in our meta-analytic estimates
did decrease for some variables in this analysis, and the weak lipid
association in ALSPAC was primarily driven by the whole blood sam-
ples. In addition, the sample size for ALSPAC was comparatively small,
and the cell proportion measures only estimated, albeit by a previously
validated method with an accuracy ‘within 10%, and often less than
5%.’ (Houseman et al., 2012) To minimise measurement error in the
mtDNA CN, a calibrator was used to control for between-plate eﬀects.
Moreover, we controlled for a wide array of variables (laboratory
covariates, sociodemographic confounders, and haematological para-
meters) which may have explained the observed associations. None-
theless, it is possible that the association with total cholesterol in
ALSPAC may be due to residual confounding, for example, due to
measurement error in the estimated cell proportions.
It is important to note that we studied peripheral blood mtDNA CN,
and cannot necessarily extrapolate our ﬁndings to those which we
might have observed, had we studied target tissues of interest (e.g.
cardiomyocytes, endothelial cells). In animal studies, some correlation
has been found between mtDNA CN assayed in the blood, adipose
tissue, liver and mammary gland of dairy cows, suggesting that in this
case, blood mtDNA CN is an appropriate proxy for other tissues
(Laubenthal et al., 2016). However, clearly these results may not ne-
cessarily apply to human subjects. Nevertheless, human studies have
successfully used peripherally assayed mtDNA CN to proxy for a tissue
of interest; Pyle et al. found concordant depletion of mtDNA CN in
peripheral white blood cells, as well as substantia nigra tissue from
patients with Parkinson's disease (Pyle et al., 2016). Moreover, Huang
et al. observed depletion of mtDNA CN in a case-control study of car-
diac failure, and noted a strong (Pearson's r= 0.718) correlation be-
tween mtDNA CN assayed in blood and in cardiomyocytes, although
their sample was small (Huang et al., 2016). From these studies, we
might therefore speculate that our results should be applicable to tis-
sues of relevance to cardiovascular disease, although we cannot state
this with certainty.
Whilst this paper only studied mtDNA CN, an extension of our work
could be to examine associations between mtDNA sequence variation
(e.g. single-nucleotide polymorphisms, [SNPs], and structural variants)
in relation to cardiometabolic risk factors. MtDNA haplogroups have
also been analysed in relation to coronary artery disease (Koﬂer et al.,
2009; Chinnery et al., 2010), diabetes (Chinnery et al., 2007), lipid
proﬁles (Hulgan et al., 2011), blood pressure (Rea et al., 2013), obesity
(Nardelli et al., 2013), CRP (Koﬂer et al., 2009), and many others
(Samuels et al., 2006), but consensus amongst ﬁndings is limited, and
well-powered studies are needed to detect these eﬀects (Samuels et al.,
2006). Accordingly, very large studies have had success in replicating
certain associations between mtDNA SNPs (and haplogroups) and age-
related disease (Hudson et al., 2014). The 4977 bp deletion (Cortopassi
and Arnheim, 1990) has been related to cardiac endpoints (Corral-
Debrinski et al., 1992) (although conclusions vary (Arai et al., 2003)),
but whilst this variant is common in post-mitotic tissue, its prevalence
may be lower in peripheral blood (Zabihi Diba et al., 2016), and so age-
related associations may be harder to detect (Mohamed et al., 2006).
Despite this, studies examining this deletion (assayed in blood) and
cardiometabolic risk factors exist (Botto et al., 2005), but larger, well-
powered studies are warranted.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.mito.2017.08.007.
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